Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Skye's CB1 blocker fails to reduce weight in obesity study
Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class.
James Waldron
Oct 6, 2025 7:55am
Pfizer’s new prize Metsera touts 14% weight loss for GLP-1
Sep 30, 2025 6:40am
Lilly withdraws phase 2 obesity trial before starting enrollment
Sep 25, 2025 8:07am
Pfizer inks $4.9B Metsera buyout to beef up obesity pipeline
Sep 22, 2025 7:47am
QL Biopharm links monthly GLP-1 to incumbent-rivaling efficacy
Sep 18, 2025 7:20am
Novo seeks obesity refresh with $550M Replicate deal
Aug 28, 2025 7:00am
